Huma and UCB to Provide Digital Health Solution for Myasthenia Gravis
Huma Therapeutics, a leading global digital health company, and UCB, a global biopharmaceutical company, are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis (MG), better understand and manage their condition with the support of their clinician. The digital platform is launching in Europe ahead of international expansion.
The technology platform is founded on Huma’s EU MDR Class IIb regulated Software as a Medical Device (SaMD) – the only disease agnostic SaMD to receive this level of EU MDR regulatory classification to-date. It will provide patients with access to MG-specific, trusted educational materials, and the ability to report and track their symptoms over time using the MG-Activities of Daily Living Scale (MG-ADL). These data are shared with clinicians through a web-based dashboard to detect exacerbations in symptoms early and intervene where necessary. Identifying exacerbation triggers will support proactive clinical decision-making and should improve patient experience. Patients can download summary reports of their health data to discuss with their clinician to maximise in-person consultations.
Dan Vahdat, CEO and Founder of Huma, said: “There has been a huge growth in drug development for rare diseases and creating treatments for this population requires a greater degree of personalisation, which is exactly what our digital health platform provides. Our new classification of Class IIb level regulation means that we can work more collaboratively and in a shorter time frame with our pharma partners to launch solutions with predictive algorithms that can have a major impact for patients at the individual level, that’s why our approach is revolutionary. We’re excited to partner with UCB and be able to bring benefit to rare disease patients again, which is where we began when the company launched over a decade ago.”
The partnership is part of UCB’s approach to offer a patient-centred approach to transform the way care is delivered to rare disease populations in a meaningful, tangible, and real-world setting.
Charl van Zyl, Executive Vice President Neurology & Head Of Europe/International Markets at UCB, said: “UCB is working to enable people with rare diseases to live the best life that they can. Symptoms of Myasthenia gravis can vary greatly and each person experiences the disease in a uniquely personal way. We believe that innovations in digital health solutions can offer the necessary personalised support, education, and resources for each patient.”
Colin Lake, Vice President, Head of Digital Care Transformation, Neurology, Head of Digital Rare Disease UCB, said: “This digital solution is an important first step in demonstrating UCB’s commitment to the rare disease community. We are beginning in Myasthenia gravis and we have the ambition to expand to other rare diseases. We’re delighted to work with Huma as we believe that partnerships are key to creating the best-in-class patient experience for patients across the rare disease community.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more